There are currently 56 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
NCT05938478
Recruiting
The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whether pregnant people who have been exposed to tralokinumab during pregnancy experience any differences in pregnancy and infant outcomes compared to women with atopic dermatitis who have not been exposed to tralokinumab during pregnancy. Participants are not required to take tralokinumab during the s... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
01/26/2025
Locations: University of California San Diego (UCSD), La Jolla, California
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
NCT06524635
Recruiting
Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD. Lutikizumab (ABT-981) is an investigational drug being developed for the treatment of HS and AD. This study will consist of 2 sub-studies: Sub-Study 1 moderate to severe hidradeni... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: Physioseq, LLC /ID# 267266, Sacramento, California +1 locations
Conditions: Hidradenitis Suppurativa, Atopic Dermatitis
Register for Updates
Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526
Recruiting
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
01/13/2025
Locations: Johns Hopkins Univerisity, Baltimore, Maryland
Conditions: Atopic Dermatitis
Register for Updates
Registry for Systemic Eczema Treatments
NCT06136767
Recruiting
The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.
Gender:
ALL
Ages:
Between 1 year and 26 years
Trial Updated:
01/13/2025
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Atopic Dermatitis
Register for Updates
CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
NCT06238765
Recruiting
Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
01/08/2025
Locations: CorEvitas, LLC, Waltham, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
NCT00177268
Recruiting
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2025
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
NCT06627335
Recruiting
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
NCT06259669
Recruiting
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Gender:
FEMALE
Ages:
Between 15 years and 50 years
Trial Updated:
12/05/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107
Recruiting
Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic di... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
NCT03936335
Recruiting
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
10/16/2024
Locations: Regeneron Research Site, Boston, Massachusetts
Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Register for Updates
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258
Recruiting
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
10/03/2024
Locations: Lurie Children's Hospital/Northwestern University, Chicago, Illinois
Conditions: Atopic Dermatitis, Sleep Disturbance
Register for Updates
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
NCT06300697
Recruiting
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various time... Read More
Gender:
ALL
Ages:
Between 10 years and 55 years
Trial Updated:
09/17/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis, Food Allergy, Healthy
Register for Updates